Kissel Pharmaceutical

Kissei Pharmaceutical is a prominent Japanese pharmaceutical company headquartered in Matsumoto, Nagano, specializing in the research and development of innovative therapies. Established in 1946, the company has built a strong reputation in therapeutic areas such as urology, nephrology, dialysis, and metabolic diseases. Its commercial portfolio is highlighted by Silodosin, a leading treatment for benign prostatic hyperplasia, and Linzagolix, an oral GnRH antagonist for women's health. Kissei actively pursues global expansion through strategic licensing agreements and partnerships with international biotech firms. The company remains committed to addressing unmet medical needs through its dedicated R&D centers and manufacturing facilities in Japan.